These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 33072137)

  • 1. Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy.
    Nüssing S; Trapani JA; Parish IA
    Front Immunol; 2020; 11():589641. PubMed ID: 33072137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of immune checkpoint therapy for cancer.
    Fritz JM; Lenardo MJ
    J Exp Med; 2019 Jun; 216(6):1244-1254. PubMed ID: 31068379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reinvigorating exhausted CD8
    Hossain MA; Liu G; Dai B; Si Y; Yang Q; Wazir J; Birnbaumer L; Yang Y
    Med Res Rev; 2021 Jan; 41(1):156-201. PubMed ID: 32844499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.
    Tsai HF; Hsu PN
    J Biomed Sci; 2017 May; 24(1):35. PubMed ID: 28545567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
    Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
    J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.
    Śledzińska A; Menger L; Bergerhoff K; Peggs KS; Quezada SA
    Mol Oncol; 2015 Dec; 9(10):1936-65. PubMed ID: 26578451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK Cell Dysfunction and Checkpoint Immunotherapy.
    Bi J; Tian Z
    Front Immunol; 2019; 10():1999. PubMed ID: 31552017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Aging and Immunotherapy in Cancer.
    Kaiser M; Semeraro MD; Herrmann M; Absenger G; Gerger A; Renner W
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of costimulatory and inhibitory receptors in FoxP3
    Toker A; Ohashi PS
    Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the epigenome to reinvigorate T cells for cancer immunotherapy.
    Xiong D; Zhang L; Sun ZJ
    Mil Med Res; 2023 Dec; 10(1):59. PubMed ID: 38044445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy.
    Jiang W; He Y; He W; Wu G; Zhou X; Sheng Q; Zhong W; Lu Y; Ding Y; Lu Q; Ye F; Hua H
    Front Immunol; 2020; 11():622509. PubMed ID: 33633741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regulation of T-cell immune exhaustion and cancer immunotherapy].
    Eikawa S; Udono H
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1066-70. PubMed ID: 25248889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel targets for immunotherapy associated with exhausted CD8 + T cells in cancer.
    Zhang L; Zhang B; Li L; Ye Y; Wu Y; Yuan Q; Xu W; Wen X; Guo X; Nian S
    J Cancer Res Clin Oncol; 2023 May; 149(5):2243-2258. PubMed ID: 36107246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
    Chen X; Song X; Li K; Zhang T
    Front Immunol; 2019; 10():292. PubMed ID: 30863404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
    Lucca LE; Hafler DA
    Immunol Rev; 2017 Mar; 276(1):9-25. PubMed ID: 28258696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
    Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
    Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.